Bionano Genomics (BNGO) Common Equity (2017 - 2025)
Bionano Genomics (BNGO) has disclosed Common Equity for 9 consecutive years, with $44.4 million as the latest value for Q4 2025.
- Quarterly Common Equity rose 25.58% to $44.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.4 million through Dec 2025, up 25.58% year-over-year, with the annual reading at $44.4 million for FY2025, 25.58% up from the prior year.
- Common Equity hit $44.4 million in Q4 2025 for Bionano Genomics, down from $49.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $362.7 million in Q1 2021 to a low of $35.4 million in Q4 2024.
- Historically, Common Equity has averaged $180.5 million across 5 years, with a median of $166.9 million in 2023.
- Biggest five-year swings in Common Equity: surged 8709.49% in 2021 and later plummeted 64.24% in 2024.
- Year by year, Common Equity stood at $337.1 million in 2021, then fell by 26.02% to $249.4 million in 2022, then tumbled by 61.44% to $96.2 million in 2023, then tumbled by 63.21% to $35.4 million in 2024, then increased by 25.58% to $44.4 million in 2025.
- Business Quant data shows Common Equity for BNGO at $44.4 million in Q4 2025, $49.8 million in Q3 2025, and $45.4 million in Q2 2025.